Creative Biolabs launches an advanced mRNA platform integrating in silico structural prediction and polymer-based delivery development to accelerate mRNA therapeutics and iPSC reprogramming.
SHIRLEY, NY, November 21, 2025 /24-7PressRelease/ — With the rapid development of mRNA therapeutics, Creative Biolabs announces a major upgrade to its mRNA technology platform—now offering an integrated, end-to-end solution that spans design, delivery, and functional validation. In addition, the company is extending the application of its mRNA technologies into iPSC (induced pluripotent stem cell) reprogramming, creating new opportunities for regenerative medicine and cell-based therapies.
The platform’s in silico mRNA structural prediction capability enables detailed analysis of mRNA secondary structures and three-dimensional conformations using computational modeling, dynamic programming algorithms, and nearest-neighbor free-energy rules. The system supports multiple sequence alignment, conserved structure identification, primer design, and promoter analysis, empowering researchers to optimize mRNA constructs from the earliest stages of molecular design. This service can function independently or as a support to other mRNA development workflows.
Creative Biolabs provides customized polymer (polyplex) development services at the delivery level. By complexing cationic polymers—such as polyethyleneimine (PEI), PDMAEMA, and others—with mRNA molecules, the platform generates nanoscale polyplexes with enhanced stability and high cellular uptake efficiency. The team adjusts the polymer type, molecular weight, geometry, and N/P ratios to optimize carrier performance. These polyplex systems significantly improve mRNA stability in vivo and promote efficient intracellular release, serving as critical enablers for mRNA therapeutics (gene therapy, protein-replacement, etc.).
In addition to therapeutics, Creative Biolabs has adapted its mRNA platform to iPSC reprogramming. The company’s self-developed mRNA-based reprogramming service, which is also non-integrative and footprint-free, allows the expression of reprogramming factors (OCT4, SOX2, KLF4, and GLIS1) to be sustained through repeated transfection of mRNA. This approach generates iPSCs with high efficiency while eliminating the genomic integration risks associated with viral vectors. The method is not only safe but also highly scalable, supporting cell quantities ranging from millions to billions.
Creative Biolabs reports that integrating these capabilities—structure-level design, optimized polymeric delivery, and mRNA-driven cell reprogramming—gives clients a truly unified and streamlined mRNA development pathway, accelerating projects from early construct optimization to functional demonstration.
As mRNA technologies continue to expand across gene therapy, cancer vaccines, regenerative medicine, and cell therapy, the enhanced platform positions Creative Biolabs to support a wide spectrum of pharmaceutical, biotechnology, and academic programs worldwide.
About
Creative Biolabs is a biotechnology company with extensive experience in nucleic acid and biomacromolecule technology development. The company offers comprehensive services including antibody discovery, gene synthesis, mRNA synthesis and delivery, and cell reprogramming solutions.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
